New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
May 26, 2015
13:23 EDTKRCKilroy Realty, community groups reach compromise on One Paseo project
Subscribe for More Information
09:38 EDTBMYuniQure reports collaboration with Bristol-Myers closed, triggers $50M payment
uniQure (QURE) announced the closing of its strategic collaboration with Bristol-Myers Squibb (BMY) to develop gene therapies for cardiovascular disease. The transaction was previously announced on April 6. Under the terms of the agreement, Bristol-Myers Squibb will make near-term payments of approximately $100M, including an initial upfront payment of $50M upon closing of the transaction, a $15M payment upon selection of three collaboration targets, in addition to S100A1, to be made within three months of closing, and an initial equity investment in uniQure representing 4.9% of the total number of shares outstanding following such issuance, at a purchase price of $33.84 per share, or approximately $37M in total. The initial equity investment is expected to close on June 12. Bristol-Myers-Squibb will acquire an additional 5.0% ownership before December 31, at a 10% premium, and has been granted two warrants, each to acquire up to an additional 5% equity interest, at a premium, based on additional targets being introduced into the collaboration. The parties have also agreed to enter into a supply contract, under which uniQure will undertake manufacturing of all gene therapy products under the collaboration. uniQure will also be eligible to receive research, development and regulatory milestone payments, including up to $254M for the lead S1A001 therapeutic and up to $217M for each other gene therapy product potentially developed under the collaboration. Additionally, uniQure is eligible to receive net sales based milestone payments and tiered single to double-digit royalties on product sales.
08:14 EDTJNJBoston Biotech Conferences to hold a conference
Subscribe for More Information
07:37 EDTBMYBristol-Myers opportunity in renal cell over $2B, says JPMorgan
Subscribe for More Information
May 22, 2015
10:52 EDTBMY, JNJJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
08:17 EDTJNJJohnson & Johnson reports STELARA receives CHMP positive opinion
Janssen-Cilag announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency adopted a positive opinion recommending approval for the use of STELARA for the treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
07:33 EDTBMYBristol-Myers receives positive CHMP opinion for Nivolumab
Subscribe for More Information
May 21, 2015
17:08 EDTJNJJohnson & Johnson Chief Accounting Officer Stephen Cosgrove to retire in October
Subscribe for More Information
11:04 EDTVRTXVertex has conference call hosted by JPMorgan
JPMorgan Analyst Kasimov hosts a conference call with CFO Ian Smith on May 26 at 1 pm.
10:30 EDTVRTXVertex management to meet with Maxim
Subscribe for More Information
09:02 EDTGRMNMio announces strategic relationship with Garmin International
Subscribe for More Information
07:37 EDTBMYPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
16:26 EDTJNJOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
11:34 EDTPBRStocks with call strike movement; PBR VALE
Subscribe for More Information
10:37 EDTCATCaterpillar April update seems negative for earnings power, says Wells Fargo
Subscribe for More Information
10:29 EDTJCPOptions with decreasing implied volatility
Options with decreasing implied volatility: ZIOP KING ARIA CTRP WTW VHC XON KERX VIPS JCP
10:26 EDTJNJJanssen acquires licence from Novo Nordisk for autoimmune disease development
Novo Nordisk (NVO) announced it has signed an agreement with Janssen Biotech (JNJ) under which Janssen will acquire an exclusive global license to further develop and commercialize a clinical program focused on therapy within autoimmune diseases. The program targets modulation of certain immune cells via a cell surface receptor, specifically the NKG2D receptor. Terms of the agreement have not been disclosed.
10:16 EDTJCPHigh option volume stocks
Subscribe for More Information
09:34 EDTSTRASenate Health, Ed, Labor & Pensions Committee to hold a hearing
The Committee holds a hearing entitled, "Reauthorizing the Higher Education Act: Exploring Institutional Risk-Sharing" with Executive Chairman of Strayer Education, Robert Silberman on May 20 at 10 am. Webcast Link
09:14 EDTCATCaterpillar reports retail machines sales down 11% in three months end April
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use